Thaum Lub Ib Hlis 7, 2026, Aktis0ncol0gy, lub tuam txhab biopharmaceutical tshwj xeeb hauv cov tshuaj radiopharmaceuticals, tshaj tawm nws qhov kev nthuav qhia thawj zaug rau pej xeem ntawm 17650.000 feem ntau ntawm tus nqi ntawm $ 18.00 ib feem. Tsis tas li ntawd, Aktis tau tso cai rau cov neeg sau ntawv hauv 30 hnub xaiv los yuav txog 2647500 qhov sib koom ua ke ntxiv ntawm tus nqi pib rau pej xeem, rho tawm cov nqi txo qis thiab cov nyiaj ua haujlwm.
1. General Specification (hauv Tshuag)
(1) API (Ntshiab hmoov)
(2) Cov ntsiav tshuaj
(3) Capsules
(4) Txau
(5) Pill press machine
https://www.achievechem.com/pill-xwm
2.Customization:
Peb yuav sib tham tus kheej, OEM / ODM, Tsis muaj hom, rau kev tshawb nrhiav kev ruaj ntseg nkaus xwb.
PIB: BM-2-4-009
Tirzepatide CAS 2023788-19-2
Lub khw tseem ceeb: Tebchaws Asmeskas, Australia, Brazil, Nyiv, Lub Tebchaws Yelemees, Indonesia, UK, New Zealand, Canada thiab lwm yam.
Chaw tsim tshuaj paus: BLOOM TECH Xi'an Hoobkas
Peb muabtirzepatide hmoov, thov xa mus rau lub vev xaib hauv qab no kom paub meej specifications thiab cov ntaub ntawv khoom.
Khoom siv:https://www.bloomtechz.com/news/peptides-nqi- npe- ntawm-bloom-tech-85355837.html
Tag nrho cov nyiaj tau los ntawm qhov kev tshaj tawm no (ua ntej txiav tawm cov nqi luv nqi, cov nyiaj them poob haujlwm, thiab cov nqi them los ntawm Aktis) xav tias yuav yog kwv yees li $ 318 lab, tsis suav nrog kev siv cov kev xaiv ntau tshaj los ntawm cov neeg sau ntawv. Txhua yam khoom lag luam yog muab los ntawm Aktis. Akis 'cov khoom lag luam feem ntau xav tias yuav pib ua lag luam ntawm NASDAQ thaum Lub Ib Hlis 9, 2026, nrog cov cai Tshuag "AKTS". Qhov kev tshaj tawm no yuav tsum ua kom tiav thaum Lub Ib Hlis 12, 2026, raws li kev cai xa khoom.
Los ntawm qhov tseem ceeb ntawm nws txoj kev lag luam, Aktis Oncol0gy tsom mus rau kev tsim cov tshuaj alpha particle radiopharmaceuticals rau kev kho cov qog nqaij hlav, thiab nws txoj kev tshawb fawb thiab kev loj hlob kav dej muaj peev xwm zoo. Ntawm lawv, AcAKY-1189, uas lub hom phiaj mob qog noj ntshav qhia txog Nectin-4, tau ua ntau qhov chaw kuaj mob Phase 1b hauv Tebchaws Meskas thiab tam sim no nrhiav txog 150 tus neeg mob. Cov txiaj ntsig ua ntej yuav tsum tau tshaj tawm hauv thawj peb lub hlis twg ntawm 2027;
Lwm qhov Ac-AKY-2519 lub hom phiaj B7-H3 qog nqaij hlav yog npaj yuav xa daim ntawv thov IND (Tshuaj Kho Tshuaj Kho Mob Daim Ntawv Thov) hauv xyoo 2026, tso lub hauv paus rau kev tshawb fawb thiab kev loj hlob ntxiv. Tsis tas li ntawd, lub tuam txhab tau tsim kev koom tes hauv tsev thiab thoob ntiaj teb isotope muab kev koom tes, nqis peev hauv kev tsim kho cov khoom siv hauv cGMP kev koom tes (xav tias yuav ua haujlwm rau 20 lub xov tooj cua hauv xov tooj cua) thiab kev ua haujlwm ntawm microphone. conjugates tej yaam num los tsim kom muaj kev R & D thiab kev txhawb nqa kev tsim khoom.
Kev vam meej Phaj I Kawm txog Kev Kho Mob Psoriatic Arthritis nrog Terpotide Ua ke nrog Yiqizhu Monoclonal Antibody
Thaum Lub Ib Hlis 8, 2026, Eli Lilly tau tshaj tawm cov txiaj ntsig zoo hauv Theem 1b TOGETHER PsA txoj kev tshawb fawb ntawm Zepbound ua ke nrog TaltzZ rau kev kho mob ntawm lub xub pwg nyom (PsA) hauv cov rog rog lossis rog rog. Txoj kev tshawb no yog thawj zaug tswj kev sim tshuaj ntsuam xyuas kev sib xyaw ntawm GLP-1 tshuaj thiab PsA biologics.
Zepbound yog GIPR/GLP-IR agonist uas tau pom zoo los ntawm FDA rau kev kho mob ntawm obstructive pw tsaug zog apnea thiab rog lossis rog. Taltz (Yiqizhu monoclonal antibody) yog ib qho tshuaj tiv thaiv-17A monoclonal antibody uas tau pom zoo los ntawm FDA rau kev kho mob ntawm active psoriatic mob caj dab, plaque psoriasis, active ankylosing spondylitis, thiab active non radiological axial spondyloarthritis.
Kev tshawb fawb TOGETHER PsA yog 52 lub lis piam randomized, multicenter, ntsuas qhov muag tsis pom, qhib daim ntawv lo theem 1b kev sim tshuaj (n=271) uas ntsuas qhov ua tau zoo thiab kev nyab xeeb ntawm TalLz thiab Zepbound hauv kev sib xyaw nrog Taltz ib leeg hauv cov neeg laus uas muaj mob psoriatic mob caj dab nyuaj dua los yog kev rog dhau los 30kg / m2, los yog BMI ntau dua lossis sib npaug li 27kg / m2 tab sis<30 kg/m2) and at least one weight related complication. The main endpoint of the study was the proportion of recipients who achieved both ACR50 response and weight loss of ≥ 10% at week 36.
Hais txog kev nyab xeeb, cov xwm txheej tsis zoo hauv pab pawg Zepbound kev sib xyaw ua ke feem ntau yog me me mus rau nruab nrab, thiab cov hom tau ua raws li kev paub txog kev nyab xeeb ntawm txhua yam tshuaj. Cov xwm txheej tsis zoo uas muaj qhov tshwm sim ntau dua lossis sib npaug li 5% hauv pawg no suav nrog xeev siab, raws plab, cem quav, thiab qhov chaw txhaj tshuaj; Cov xwm txheej tsis zoo hauv pawg Taltz monotherapy yog qhov chaw txhaj tshuaj thiab kab mob ua pa sab sauv.
Lilly lub me me molecule GLP-1R agonist thov rau npe hauv Suav teb
Thaum Lub Ib Hlis 10, 2026, CDE lub vev xaib tau pom tias Eli Lilly lub me me molecule GLP-1R agonist, 0rforglpron, tau tshaj tawm rau kev ua lag luam hauv Suav teb. Yav dhau los, cov tshuaj tau suav nrog FDA pom zoo cov npe tshuaj nyob rau lub Kaum Ib Hlis 2025, thiab Eli Lilly tau xa daim ntawv thov kev lag luam rau cov tshuaj kom poob phaus rau FDA thaum Lub Kaum Ob Hlis 2025.
Txog rau tam sim no, Aoqiglielon tau ua tiav xya qhov kev tshawb fawb Theem I, suav nrog plaub rau cov neeg mob ntshav qab zib hom 2 (ACHIEVE-1, ACHIEVE-2, ACHEVE-3, ACHIEVE-5), ob qho rau cov neeg rog lossis rog (ATTACIN-1, ATTACIN-MAINTAIN), thiab ib qho rau cov rog rog lossis 22 cov neeg rog rog (hom mob ntshav qab zib hom 2). Cov txiaj ntsig tseem ceeb kuj tau nthuav tawm.
0rforglipron yog ib qho niaj hnub qhov ncauj me me molecule GLP-1 receptor agonist tshawb pom los ntawm Suav thiab txawv teb chaws cov tuam txhab tshuaj thiab tsim thoob ntiaj teb los ntawm Lilly, uas yog siv los kho hom 2 mob ntshav qab zib thiab rog. Raws li lub ntiaj teb qhov ze tshaj plaws ntawm qhov ncauj me me molecule GLP-1 tshuaj rau kev ua lag luam, 0rforglipron tau ua tiav theem kuv qhov kev sim tshuaj thiab tau xa daim ntawv thov kev lag luam rau FDA thaum Lub Kaum Ob Hlis 18, 2024.
Raws li cov ntaub ntawv saum toj kawg nkaus ntawm ACHIEVE-3 txoj kev tshawb fawb tso tawm los ntawm Lilly thaum Lub Cuaj Hli 2025, hauv lub taub hau mus rau lub taub hau kuaj rau cov neeg mob ntshav qab zib hom 2, 0rforglipron qhov ua tau zoo hauv kev txo cov ntshav qab zib thiab qhov hnyav yog qhov zoo dua li Novo Nordisk qhov ncauj smeglutide. Cov ntaub ntawv tswj qhov hnyav yog qhov tshwj xeeb tshaj yog: pawg koob tshuaj 36mg poob qhov nruab nrab ntawm 8.9kg (qhov hnyav poob 9.2%), deb tshaj li 5.0kg (qhov hnyav poob 5.3%) ntawm qhov ncauj semaglutide 14mg pawg, nrog cov txheeb ze kom zoo dua 73.6%; Qhov nruab nrab qhov hnyav poob ntawm pawg 12mg koob tshuaj yog 6.6kg (qhov hnyav poob 6.7%), uas kuj zoo dua li 3.6kg (qhov hnyav poob 3.7%) ntawm qhov ncauj semaglutide 7mg pawg.